drugset / Trial / NCT02413918
Iloperidone in Mixed States of Bipolar Disorder
Phase 4
Completed
41 enrolled
The University of Texas Health Science Center at San Antonio
Novartis Pharmaceuticals · collabVanda Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD. 2. To assess background, baseline features, and behavioral components which characterize treatment response/non-response in the acute and long term management of MS
Timeline
- Start
- 2012-04
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iloperidone | Small molecule | 6 mg | Oral |
| Subject | Iloperidone | Small molecule | 12 mg | Oral |
| Subject | Iloperidone | Small molecule | 24 mg | Oral |